Societe Generale S.A. (GLE)
Euronext Paris · France · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 59.66 |
|---|---|
| 52-week range | 52.02 – 84.82 |
| Return, 1 month / 3 months | −16.5% / −20.4% |
| Return, 1 year / 3 years | +14.2% / +211.2% |
| Trend | Below its 200-day average |
| RSI (14) | 28 |
| Volatility (1 year) | 35.2% |
| Worst drawdown (1 year) | -28.4% |
| Average daily value traded | 142.93M EUR |
| Dividend yield | 2.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Societe Generale is a French banking group based in Paris. It serves individual customers, small businesses, large companies and institutional clients through retail banking networks in France and other countries, alongside corporate and investment banking, asset management, insurance and securities services. Its retail operations include the Societe Generale and Credit du Nord brands, while its wholesale arm handles financing, advisory and market activities for corporate and institutional clients around the world.
Societe Generale S.A. trades under the code GLE on the Euronext Paris in France, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Societe Generale S.A. (GLE) trades on the Euronext Paris in France. It last closed at EUR 59.66 on 23 October 2026.
Its price-based Market X-Ray is 60 out of 100 (a fair price profile), ranking 218 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 14.2% and over the last three months it fell 20.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 49 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -15.4% | ||
| From 52-week high | -29.2% | ||
| Momentum | 53 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -20.3% | ||
| 6-month return | -12.2% | ||
| 12-month return, skipping the last month | 36.8% | ||
| Stability (higher is calmer) | 60 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 35.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -28.4% | ||
| Liquidity | 99 · Strong | Trades actively. | |
| Average daily value traded | 142.93M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 46 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.9% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Income: Dividend is small or irregular.
Returns
| 1 week | −7.5% |
|---|---|
| 1 month | −16.5% |
| 3 months | −20.4% |
| 6 months | −12.2% |
| 1 year | +14.2% |
| 3 years | +211.2% |
| 5 years | +164.7% |
Signals
| 50-day / 200-day average | 69.85 / 70.52 |
|---|---|
| Golden / death cross (60 days) | Death, 1 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.01 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 5 Oct 2026 | EUR 0.7500 |
| 1 Jun 2026 | EUR 1.0000 |
| 7 Oct 2025 | EUR 0.6100 |
| 26 May 2025 | EUR 1.0900 |
| 29 May 2024 | EUR 0.9000 |
| 30 May 2023 | EUR 1.7000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.